All In Biotech

Drug Trial Radar · NCT06770933

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

A Phase II, Double-Masked, Randomised, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy OF Non-Proliferative Type (NPDR)

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 11, 2025

Primary completion

Jul 2027

Study completion Oct 2027

Sponsor

Lead sponsor
Vantage Biosciences LtdIndustry
Sponsor type
Industry
Collaborators
Vantage Biosciences Australia Pty Ltd
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.

Conditions

  • Diabetic Retinopathy
  • NPDR - Non Proliferative Diabetic Retinopathy

Interventions

  • VX-01Drug

    There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.

  • PlaceboDrug

    Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy of oral doses of VX-01 in subjects compared to placebo following 1 year of treatment.Time frame: From enrollment to the end of treatment at week 52

Locations

27 sites in 5 countries. Site status is shown where the registry gives one.

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Stanford Byers Eye Institute

    Palo Alto, California

  • California Retina Consultants- Santa Barbara

    Santa Barbara, California

  • Florida Retina Institute - Jacksonville Southside

    Jacksonville, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Sterling Vision, PC

    Eugene, Oregon

  • Erie Retina Research

    Erie, Pennsylvania

  • Piedmont Eye Center

    Lynchburg, Virginia

  • Eye Clinic Albury Wodonga

    Albury, New South Wales, Australia

  • Retina And Eye Consultants Hurstville

    Hurstville, New South Wales, Australia

  • Marsden Eye Specialists

    Parramatta, New South Wales, Australia

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia

  • Sydney Retina Clinic

    Sydney, New South Wales, Australia

  • Sydney West Retina

    Westmead, New South Wales, Australia

  • University of the Sunshine Coast Clinical Trials (Birtinya)

    Birtinya, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Prince of Wales Hospital The Chinese University of Hong Kong

    Shatin, Hong Kong

  • HKU Eye Centre

    Wong Chuk Hang, Hong Kong

  • Hospital Selayang

    Selayang Baru Utara, Malaysia

  • University Malaya Medical Centre

    Petaling Jaya, Kuala Lumpur Federal Territory of Kuala Lumpur, Malaysia

  • Hospital Pulau Pinang

    George Town, Pulau Pinang, Malaysia

  • Hospital Shah Alam

    Shah Alam, Selangor, Malaysia

  • Hospital Al-sultan Abdullah Uitm

    Sungai Buloh, Selangor, Malaysia

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.